Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Microbot Medical Inc (NQ: MBOT ) 0.9461 -0.0087 (-0.91%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Microbot Medical Inc < Previous 1 2 3 Next > Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025 October 15, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up September 30, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System September 17, 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System August 22, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization August 13, 2024 The ISO 13485 certification is a validation of the Company’s robust quality system From Microbot Medical Inc. Via GlobeNewswire Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System August 01, 2024 The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center July 18, 2024 As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial July 09, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial July 08, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial July 03, 2024 Following the Company’s recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial June 20, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial June 17, 2024 The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules June 04, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules June 03, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial June 03, 2024 The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k)... From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™ April 29, 2024 The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Shares Status Following Recent Geopolitical Events April 15, 2024 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US February 05, 2024 The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters January 30, 2024 All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study January 18, 2024 Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules December 29, 2023 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met December 28, 2023 The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study From Microbot Medical Inc. Via GlobeNewswire Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic December 14, 2023 The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study December 07, 2023 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities November 21, 2023 The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process November 13, 2023 The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office November 08, 2023 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study October 31, 2023 Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024 October 24, 2023 From Microbot Medical Inc. Via GlobeNewswire Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company October 19, 2023 From Microbot Medical Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
